HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine.

AbstractOBJECTIVES:
The primary objective is to reveal the effect of hydroxychloroquine (HCQ) treatment on corrected QT (QTc) interval in patients with systemic lupus erythematosus (SLE). The secondary objective is to investigate factors that affect QTc prolongation.
METHODS:
SLE patients who had electrocardiograms between 2015 and 2020 were recruited and assigned to two groups based on whether they were treated with HCQ (HCQ group) or not (control group). Change of QTc before and after HCQ administration in the HCQ group was measured and compared with the control group. Patients treated with HCQ were further divided into two groups based on presence or absence of QTc prolongation and the characteristics were compared.
RESULTS:
In total, 126 patients were recruited, of whom 42 were treated with HCQ. In the HCQ group, the mean QTc significantly increased (p < .001), while there was no significant difference of mean QTc in the control group. Moreover, those in the HCQ group with QTc prolongation showed a significantly higher proportion of hypertension and longer SLE duration compared to those without QTc prolongation. However, the multiple logistic regression analysis showed that there were no significant differences among them.
CONCLUSION:
HCQ could induce QTc prolongation in SLE patients. It might be better that the possibility of QTc prolongation was taken into consideration when HCQ was administered in the patients with longer disease duration of SLE and coincidence of hypertension.
AuthorsTaihei Nishiyama, Yuya Kondo, Hiroto Tsuboi, Hisashi Noma, Daiki Tabuchi, Toshiki Sugita, Shota Okamoto, Toshihiko Terasaki, Masaru Shimizu, Fumika Honda, Ayako Ohyama, Izumi Kurata, Mizuki Yagishita, Saori Abe, Hiroyuki Takahashi, Atsumu Osada, Shinya Hagiwara, Isao Matsumoto, Takayuki Sumida
JournalModern rheumatology (Mod Rheumatol) Vol. 31 Issue 6 Pg. 1107-1112 (Nov 2021) ISSN: 1439-7609 [Electronic] England
PMID33496215 (Publication Type: Journal Article)
Chemical References
  • Antirheumatic Agents
  • Hydroxychloroquine
Topics
  • Antirheumatic Agents (adverse effects)
  • Electrocardiography
  • Humans
  • Hydroxychloroquine (adverse effects)
  • Long QT Syndrome (chemically induced, diagnosis, drug therapy)
  • Lupus Erythematosus, Systemic (complications, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: